177 results about "Viral protein" patented technology

The application belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody specifically recognizing type II grass carp reovirus VP4 protein, a eukaryotic expression method and application. The S6 gene in GCRV-II encodes VP4 protein, the application transfects the target gene S6 into HEK293 cells for expression and purification, cooperates with Freund's adjuvant to immunize New Zealand white rabbits, and uses ELISA, single B cell screening and eukaryotic expression technology to obtain a rabbit-derived recombinant monoclonal antibody specifically recognizing GCRV-II VP4 protein. The antibody has strong specificity, provides support for further establishment of specific type II grass carp reovirus diagnosis technology, and has great application value for development of GCRV-II related scientific research.

The invention provides a porcine deltacoronavirus S1 protein nanoparticle vaccine CTDnps and application thereof, and belongs to the technical field of vaccine preparation. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled, provided by the invention, comprises ferritin and a PDCoV S1 protein C-terminal structural domain, the amino acid sequence of the ferritin is as shown in SEQ ID NO.1, and the amino acid sequence of the PDCoV S1 protein C-terminal structural domain is as shown in SEQ ID NO.2. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled comprises the ferritin and the PDCoV S1 protein C-terminal structural domain. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine (S1CTD-Fer) constructed by the invention can be self-assembled to form ferritin-like cage-shaped nanoparticles, and the hydrodynamic diameter of the cage-shaped nanoparticles is obviously greater than that of natural ferritin nanoparticles. Compared with the S1CTD, the S1CTD-Fel based on the ferritin carrier can obviously enhance the immunogenicity of the S1CTD, can obviously enhance the uptake efficiency of antigen presenting cells, and is high in safety.

The invention belongs to the technical field of biology, and particularly relates to a swine monoclonal antibody of hog cholera virus Erns protein. The amino acid sequence of a heavy chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 1, the amino acid sequence of a heavy chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 2, the amino acid sequence of a light chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 3, and the amino acid sequence of the light chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 4. The full-length genes of the heavy chain and the light chain of the swine monoclonal antibody are obtained from a swine B cell specifically amplified by the same hog cholera virus Erns protein, the natural structure of an antibody molecule is reserved, affinity loss possibly caused by artificial recombination is avoided, and the swine monoclonal antibody has high affinity and specificity, and can be used for preparing the swine monoclonal antibody. And a precise molecular tool is provided for antigen structure analysis of the hog cholera virus Erns protein and establishment of a hog cholera diagnosis method. The monoclonal antibody is applied to a blocking ELISA detection method of the hog cholera virus Erns antibody, and the established Erns antibody blocking ELISA detection method is high in sensitivity and strong in specificity.

The invention discloses preparation and application of a rabies virus G protein mRNA vaccine freeze-drying preparation, and relates to the field of veterinary biological products. According to the invention, rabies virus G protein mRNA is prepared on a large scale through an in-vitro transcription technology, and an mRNA-LNP (lipid nanoparticle) delivery system is successfully constructed by adopting a microfluidic encapsulation process. Through freeze-drying protective agent formula screening (including cane sugar, trehalose and mannitol) and freeze-drying procedure parameter optimization (including pre-freezing temperature, main drying rate and secondary drying residual moisture control), the freeze-dried mRNA vaccine preparation which can stably exist under the condition of 4 DEG C is finally obtained.

The invention belongs to the technical field of biological genetic engineering, and particularly relates to a mouse model construction scheme capable of reproducing a key phenotype of hemophagocytic syndrome, which comprises the following steps: inserting a loxP-STOP-loxP-LMP1 conditional expression cassette into a Rosa26 safe port site in a fixed point manner to obtain an Lmp1cKI mouse strain; and hybridizing the mouse with an Ncr1-Cre transgenic mouse of NK cell specific expression Cre recombinase. In a double transgenic offspring (Lmp1Ncr1-Cre), STOP fragments are cut off by Cre enzyme, and continuous high expression of EB virus LMP1 protein in NK cells is driven. The model does not need chemical induction or immune intervention, and typical hemophagocytic syndrome phenotypes, namely serum IL-6, TNF-alpha and IFN-gamma, spontaneously appear within 7-9 days after young rats are born; the body weight is reduced and the survival rate is obviously reduced; the proportion of lymphocytes is sharply reduced; and NK cells are depleted. The invention provides a stable and reliable tool for hemophagocytic syndrome pathogenesis research, drug screening and treatment evaluation.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

Provided herein is a nucleic acid encoding a prion protein, wherein the prion protein (a) comprises an amino acid sequence comprising a protective sequence variant such as a G127V mutation and (b) lacks a fully functional 3' glycosylphosphatidylinositol (GPI)-anchor attachment sequence. Also provided are viral vectors and pharmaceutical compositions comprising the nucleic acids. Further provided are methods and uses of treating prion diseases or other neurodegenerative diseases that confer toxicity through cell surface- anchored prion proteins in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition or viral vector described herein.

The invention provides a human monoclonal antibody B1AG for resisting type 4 adenovirus. The neutralizing antibody for resisting the 4-type adenovirus provided by the invention can be specifically combined with the 4-type adenovirus, and has very high affinity activity and very strong neutralizing activity at low concentration. The invention also provides application of the antibody in preparation of medicines for treating and / or preventing type 4 adenovirus diseases, and a detection kit containing the antibody.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

The invention discloses a monoclonal antibody 5B11 for recognizing an extracellular domain of peste des petits ruminants virus H protein and application of the monoclonal antibody 5B11, and belongs to the technical field of monoclonal antibodies. According to the invention, PPRV-H-185 protein with an amino acid sequence as shown in SEQ ID NO.1 is used for immunizing a mouse, a monoclonal antibody 5B11 with a neutralizing effect is prepared, a heavy chain variable region of the monoclonal antibody 5B11 comprises CDR1-3 with an amino acid sequence as shown in SEQ ID NO.7-9, and a light chain variable region of the monoclonal antibody 5B11 comprises CDR1-3 with an amino acid sequence as shown in SEQ ID NO.12-14. Experimental results show that the monoclonal antibody can be combined with a virus, so that the virus loses the ability of combining an epithelial cell H protein receptor Nectin-4 and a lymphocyte H protein receptor SLAM, and the virus is prevented from invading cells. The invention provides a new biological material for detection and prevention of peste des petits ruminants virus, and has a good clinical application prospect.

This invention discloses methanogenic lyases with the same protein family annotation as PeiR lyases and their applications. These enzymes are obtained through homology screening based on the known characteristics of PeiR lyases targeting peptide bonds in the methanogenic cell wall, using the Pfam protein family database annotation. PeiR lyase proteins participate in the biological process of hydrolyzing archaea cell walls, effectively killing methanogens and reducing methane production. Proteins homologous to this protein have potential methane-reducing potential. This invention integrates rumen microbial metagenomic sequencing data, uses a series of bioinformatics software to screen methanogenic viral proteins, and combines Pfam functional domain annotation for homology analysis, ultimately identifying a series of lyases. These lyases were successfully expressed in a prokaryotic expression system, and in vitro gas production experiments also showed that the crude enzyme solution significantly reduced methane production.

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for computationally docking a small molecule or ligand to a prion-protein In one aspect, a system comprises receiving data comprising a structure of a candidate drug, a structure of a prion-protein filament comprising one or more prions, and a location of a binding site in the prion-protein filament structure, generating a plurality of stacked pose configurations of the candidate drug using at least the candidate drug structure, determining a corresponding docking score for each stacked pose configuration in the plurality of stacked pose configurations in accordance with a measure of a likelihood of binding for the stacked pose configuration in the location of the binding site in the prion-protein filament, and taking an action based on the corresponding docking scores.

The application provides an anti-Spike protein antibody of a novel coronavirus and an application thereof. By means of genetic engineering and phage surface display library technology, specific antibodies against the S protein of the novel coronavirus are screened from a single-chain antibody library of non-immune full human sequences. The antibodies have an affinity to the S protein of the virus between 1nM and 50nM, the antibodies have an inhibiting effect on the combination of the S protein of the novel coronavirus and human receptor ACE2, and the anti-S protein antibodies of the application have a good ability to combine with the S protein and a potential neutralizing inhibiting effect. The application provides specific antibody candidate molecules for the development of diagnostic reagents, preventive and therapeutic antibody drugs against the novel coronavirus (2019-nCoV) and the treatment of other diseases such as pneumonia caused by the coronavirus.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in anti-rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing gene fragments of the ectodomain of the G glycoprotein of the Pasteur strain rabies virus, a linker of 7 amino acids (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the gp64 baculovirus protein, with the arrangement of the sequences in the designed gene cassette being shown in figure 1.

The invention provides a fully humanized monoclonal antibody for resisting SARS-CoV and SARS-CoV-2 and application of the fully humanized monoclonal antibody, and belongs to the technical field of immunology, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 1; the amino acid sequence of a light chain variable region of the monoclonal antibody SARS2-1 is as shown in SEQ ID NO: 2; the antibody has a unique CDR partition, can identify S proteins of the two viruses at the same time, and has cross-neutralization activity on pseudoviruses of the two viruses. The antibody has the characteristics of high expression, full human source and good stability, is suitable for industrial production, and has potential application value for coping with outbreak prevalence caused by coronavirus possibly occurring at present and in the future.

The invention belongs to the field of biology, and particularly relates to construction of a recombinant Seneca virus strain with Seneca virus 2B protein translation block site mutation. The 26th lysine (K) of the 2B protein is found to be a key site for inhibiting the translation of the host protein for the first time, and after the 26th K of the 2B protein is mutated into the alanine (A), the translation retardation phenomenon of the host protein is obviously weakened; secondly, the 26th K of the 2B protein is mutated into A to construct infectious clone, and the recombinant Seneca virus strain rSVA-2B K26A with 2B protein translation retardation site mutation is successfully rescued and obtained, compared with wild type SVA, after the rSVA-2B K26A infects host cells, the translation retardation phenomenon of the host cells is weakened, the expression level of host antiviral inflammatory cytokines is enhanced, and the expression level of the recombinant Seneca virus strain rSVA-2B K26A is improved. The Seneca virus vaccine strain can be used as a potential vaccine candidate strain, and a foundation is laid for developing a novel prevention and control strategy aiming at the Seneca virus.

The application provides an anti-Spike protein antibody of a novel coronavirus and an application thereof. By means of genetic engineering and phage surface display library technology, specific antibodies against the S protein of the novel coronavirus are screened from a single-chain antibody library of non-immune full human sequences. The antibodies have an affinity to the S protein of the virus between 1nM and 50nM, the antibodies have an inhibiting effect on the combination of the S protein of the novel coronavirus and human receptor ACE2, and the anti-S protein antibodies of the application have a good ability to combine with the S protein and a potential neutralizing inhibiting effect. The application provides specific antibody candidate molecules for the development of diagnostic reagents, preventive and therapeutic antibody drugs against the novel coronavirus (2019-nCoV) and the treatment of other diseases such as pneumonia caused by the coronavirus.

The invention discloses a bovine nodular skin disease virus fusion antigen as well as a product and application thereof, and belongs to the technical field of immunity. In order to solve the technical problems that the immune antigen of the bovine nodular skin disease virus is poor in safety, not easy to prepare and low in immunogenicity, the technical scheme is characterized in that the fusion antigen aiming at the bovine nodular skin disease virus is provided, and the fusion antigen comprises three antigen peptide fragments derived from bovine nodular skin disease virus LSDV060 protein and LSDV122 protein, and the three antigen peptide fragments are fused through head-to-tail splicing.

The application discloses application of a carnation Italian ring spot virus P19 protein in regulating virulence of pseudomonas aeruginosa. The application finds that the protein can regulate synthesis of pyocyanin and affect virulence of the pseudomonas aeruginosa by constructing a recombinant expression vector of the carnation Italian ring spot virus P19 protein and transferring the protein into the pseudomonas aeruginosa, and the protein can be used for preventing and treating the pseudomonas aeruginosa, and a new method for preventing and treating the pseudomonas aeruginosa is provided.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

To provide a method for producing an RSV F protein trimer by a fed-batch cell culture method.SOLUTION: Provided is a method comprising a temperature transition. The temperature is shifted to a lower temperature between about 30.0°C and about 32.0°C, preferably about 31.0°C.SELECTED DRAWING: Figure 2

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody Fab5 for recognizing EB virus gB protein and application thereof. The monoclonal antibody or antigen-binding fragment thereof has high affinity to the gB protein and can significantly inhibit the infection of EBV on epithelial cells and B cells, and the epitope of the Fab5 binding to the gB is determined through structural analysis. The antibody can be used for detecting the presence or level of the gB protein in a sample, detecting the EB virus, diagnosing diseases caused by the EB virus infection, preventing the EB virus infection and / or treating and / or preventing diseases caused by the EB virus infection.

Techniques are provided for determining pan-HLA binding of viral proteins. A trained classifier model is operable to determine, independently per HLA, at least one of (a) an average binding prediction of overlapping peptides at each position of a viral protein, (b) a maximum value of a binding prediction of overlapping peptides at each position of the viral protein, (c) standard deviation of a binding prediction of overlapping peptides at each position of the viral protein, and (d) a combination of one or more of (a)-(c). A classification engine uses the classifier model to determine average binding predictions of overlapping peptides at each position of the viral protein independently for test HLA-I and HLA-II functional groupings, where a peptide is classified as a binder when an average binding prediction corresponding to the peptide satisfies a binding value threshold.

The invention belongs to the technical field of biological medicine, and particularly relates to a detection kit for detecting new coronavirus. According to the invention, a new coronavirus NP protein is taken as an immunogen, monoclonal antibodies aiming at specific epitopes of the new coronavirus NP protein are screened, a specific strain is taken as a capture antibody, the other strain is labeled by horse radish peroxidase and taken as a detection antibody, and a double-antibody sandwich ELISA method for detecting the SARS-CoV-2 NP protein is established. Compared with the prior art, the method has the advantages that the detection time is greatly shortened, the detection can be completed in only 6 hours, and a foundation is laid for rapid detection of an SARS-CoV-2 clinical sample.

The present invention is related to method of preparing a gain-of-function mutation in poxvirus, like buffalopox virus (BPXV) by long-term propagating it in the presence of methyltransferase inhibitor like 3-Deazaneplanocin A (DZNep), which results in generation of viral 2'O-MTAse (VP39) mutant with a single point mutation (M236I). The resultant mutant has the following characteristics: (a) M236I mutation of 2'O-MTAse increases the cap-1 markings on viral mRNA; (b) The 2'O-MTAse mutant virus had hyperactive 2'O-MTAse and exhibited enhanced stability and translational efficiency of its mRNA; (c) The capping (cap1) performed by the mutant viral 2'O-MTAse (VP39) results in higher viral protein production, as compared to the wild type VP39 and (d) Mutant virus replicated at higher viral titer than the wild-type virus.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

The invention relates to a fusion protein comprising a polypeptide based on the interdomain region (IC) of Orthoreovirus muNS protein, which maintains the capacity to be incorporated into nanospheres and / or microspheres formed by the protein and a polypeptide comprising at least one motif that interacts non-covalently with SUMO (SIM).

The utility model relates to the technical field of chemiluminescence detection kit, specifically to the chemiluminescence detection kit of Seneca virus VP1 protein monoclonal antibody, including protection subassembly, the inside of the placing box is provided with clamping assembly, the clamping assembly includes the installation strip, the installation strip side surface is provided with sliding slot, the sliding slot quantity is two and the position corresponds, the sliding groove inner wall sliding connection has the slide, the slide quantity is ten and the adjacent two slides are a group, and the fixed connection has the spring between every group two slides, the slide side surface fixed connection has semicircle clamping plate, the semicircle clamping plate quantity is several and the position corresponds to adjacent two semicircle clamping plates, the installation strip side surface fixed connection is in the placing box inner wall, through the elastic clamping adaptation different specifications sampling tube, prevent it from shaking and falling off in the operation, reduce sample spilling, the protection box body can also block spilled sample when accidentally, guarantee detection.